In this current review, we analysed recently published data after 2017 on the use of AET and bone health in pre- and post-MP women with non-metastatic, hormone receptor positive (HR + ) breast cancer and included novel fracture risk assessment tools such as trabecular bone score (TBS) and vertebral fracture assessment (VFA) based on a systematic literature search strategy. The gene discussed is NR4A1; the disease is breast carcinoma.